Advertisement

Using the transtheoretical model’s stages of change to predict medication adherence in patients with type 2 diabetes mellitus in a primary health care setting

  • Yara Arafat
  • Mohamed Izham Mohamed IbrahimEmail author
  • Ahmed Awaisu
  • Stephen Colagiuri
  • Yaw Owusu
  • Donald E. Morisky
  • Mudather AlHafiz
  • Ahmed Yousif
Research Article
  • 35 Downloads

Abstract

Background

Qatar is currently experiencing a worrying increase in the prevalence of diabetes mellitus (DM). One of the most common reasons for uncontrolled DM is non-adherence to medications. The socio-behavioral intervention has proven effective in some chronic illnesses.

Objectives

To assess the stages of change (SOC) and medication adherence scores of type 2 diabetes mellitus (T2DM) patients visiting primary healthcare institutions in Qatar, and to evaluate the cause and effect relationship between SOC and adherence to antidiabetic medications.

Methods

The 8-item Morisky Medication Adherence Scale (MMAS-8) was used to assess medication adherence, and a 2-item SOC questionnaire was utilized to classify the SOC. The analysis to determine if the SOC could predict medication adherence while controlling for demographic characteristics, total number of prescribed medications and disease duration was done using hierarchical multiple regression.

Results

The final analysis included 387 patients. In relation to medication adherence, majority of the patients were in the maintenance stage (76.7%), followed by the preparation stage (14.7%), the action stage (3.9%), the contemplation stage (3.4%) and the precontemplation stage (1.3%). Most of the patients were in high adherence towards antidiabetic medications (50.3%) followed by low level (26.4%) and medium level (23.3%). SOC was significant and positively predicted medication adherence, which accounted for around 58 to 60% (p < 0.001) while controlling for covariates.

Conclusions

SOC was significant and positively predicted medication adherence. The study recommends that the SOC questionnaire could potentially be used to identify patients at risk for low adherence.

Keywords

Stages of change Transtheoretical model Diabetes mellitus Medication adherence Primary care 

Notes

Acknowledgments

Use of the ©MMAS is protected by US copyright and registered trademark laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, 294 Lindura Court, Las Vegas, NV 89138-4632; dmorisky@gmail.com.

The researchers would like to thank the Qatar Primary Health Care Corporation and staff at both primary healthcare setting for their support and cooperation throughout the study.

The manuscript was sent to American Journal of Expert for English Language service editing and was covered under the research grant.

Funding

This work was supported by the Qatar University [grant number QUUG-CPH-CPH-14/15–5].

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Dr. Morisky is the developer/owner of the copyrighted and trademarked protected Morisky Medication Adherence Scale and sells MMAS licenses and consulting services through MMAS Research LLC, 14725 NE 20th St., Bellevue, Washington 98,007. Dr. Morisky was not involved in the data collection or analysis.

Ethical approval

The study was approved by the Institutional Review Boards of Primary Health Care Corporation and Qatar University.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Kahn CR, Weir GC. Joslin’s Diabetes Mellitus. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.Google Scholar
  2. 2.
    World Health Organization. Global report on diabetes. Geneva: World Health Organization; 2016.Google Scholar
  3. 3.
    Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Trisha D, et al. IDF diabetes atlas. 6th ed. Brussels: International Diabetes Federation; 2013.Google Scholar
  4. 4.
    International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015.Google Scholar
  5. 5.
    Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26(3):917–32.Google Scholar
  6. 6.
    American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596–615.Google Scholar
  7. 7.
    Reiber GE, King H. Guidelines for the development of a national programme for diabetes mellitus. Geneva: World Health Organization; 1991.Google Scholar
  8. 8.
    Funnell MM, Anderson RM. Empowerment and self-management of diabetes. Clin Diabetes. 2004;22:123–7.Google Scholar
  9. 9.
    Engel GL. The need for a new medical model: a challenge for biomedicine. Science. 1977;196(4286):129–36.Google Scholar
  10. 10.
    Deverell A, Ross E. Psychosocial approaches to health, illness and disability. A reader for health care professionals. Pretoria: Van Schaik Publishers; 2004.Google Scholar
  11. 11.
    Blackwell B. Compliance. Psychother Psychosom. 1992;58(3):161–9.Google Scholar
  12. 12.
    World Health Organization. Constitution of the world health organization. Geneva: World Health Organization; 1946.Google Scholar
  13. 13.
    Prochaska JO, DiClemente CC. Toward a Comprehensive Model of Change. In: Toward a comprehensive model of change. New York: Springer; 1986.Google Scholar
  14. 14.
    Prochaska JO, Norcross JC. Systems of pscyhotherapy: a transtheoretical analysis. 7th ed. California: Brooks-Cole; 2010.Google Scholar
  15. 15.
    Ahmadipour H, Farajzadegan Z, Kachoei A, Pirdehghan A. Secondary prevention by enhancing adherence in diabetic patients. Int J Prev Med. 2010;1(1):50–5.Google Scholar
  16. 16.
    Willey C. Behavior-changing methods for improving adherence to medication. Curr Hypertens Rep. 1999;1(6):477–81.Google Scholar
  17. 17.
    Johnson SS, Driskell MM, Johnson JL, Prochaska JM, Zwick W, Prochaska JO. Efficacy of a transtheoretical model-based expert system for antihypertensive adherence. Dis Manag. 2006;9(5):291–301.Google Scholar
  18. 18.
    Johnson SS, Driskell MM, Johnson JL, Dyment SJ, Prochaska JO, Prochaska JM, et al. Transtheoretical model intervention for adherence to lipid-lowering drugs. Dis Manag. 2006;9(2):102–14.Google Scholar
  19. 19.
    Genberg BL, Lee Y, Rogers WH, Willey C, Wilson IB. Stages of change for adherence to antiretroviral medications. AIDS Patient Care STDs. 2013;27(10):567–72.Google Scholar
  20. 20.
    Tuldra A, Wu AW. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(3):154–7.Google Scholar
  21. 21.
    Partapsingh VA, Maharaj RG, Rawlins JM. Applying the stages of change model to type 2 diabetes care in Trinidad: a randomised trial. J Negat Results Biomed. 2011;10(1):13.Google Scholar
  22. 22.
    Parchman ML, Arambula-Solomon TG, Noel PH, Larme AC, Pugh JA. Stage of change advancement for diabetes self-management behaviors and glucose control. Diabetes Educ. 2003;29(1):128–34.Google Scholar
  23. 23.
    Kirk A, MacMillan F, Webster N. Application of the transtheoretical model to physical activity in older adults with type 2 diabetes and/or cardiovascular disease. Psychol Sport Exerc. 2010;11(4):320–4.Google Scholar
  24. 24.
    Jones H, Edwards L, Vallis TM, Ruggiero L, Rossi SR, Rossi JS, et al. Changes in diabetes self-care behaviors make a difference in glycemic control: the diabetes stages of change (DiSC) study. Diabetes Care. 2003;26(3):732–7.Google Scholar
  25. 25.
    Chapman-Novakofski K, Karduck J. Improvement in knowledge, social cognitive theory variables, and movement through stages of change after a community-based diabetes education program. J Acad Nutr Diet. 2005;105(10):1613–6.Google Scholar
  26. 26.
    Salmela S, Poskiparta M, Kasila K, Vahasarja K, Vanhala M. Transtheoretical model-based dietary interventions in primary care: a review of the evidence in diabetes. Health Educ Res. 2009;24(2):237–52.Google Scholar
  27. 27.
    Thompson JR, Horton C, Flores C. Advancing diabetes self-management in the Mexican American population: a community health worker model in a primary care setting. Diabetes Educator. 2007;33(6):159–65.Google Scholar
  28. 28.
    Morisky DE, Ang A, Krousel-Wood M, Ward H. Predictive validity of a medication adherence measure in a patient setting. J Clin Hyper. 2008;10(5):348–54.Google Scholar
  29. 29.
    Berlowitz DR, Foy CG, Kazis LE, Bolin L, Conroy LB, Fitzpatrick P, et al. For the SPRINT study research group. Impact of intensive blood pressure therapy on patient-reported outcomes: outcomes results from the SPRINT study. N Engl J Med. 2017;377:733–44.Google Scholar
  30. 30.
    Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: final response. J Clin Epidem. 2011;64:258–63.Google Scholar
  31. 31.
    Shaw E, Anderson JG, Maloney M, Jay SJ, Fagan D. Factors associated with noncompliance of patients taking antihypertensive medications. Hosp Pharm. 1995;30(3):201–3.Google Scholar
  32. 32.
    Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther. 2005;27(7):1064–73.Google Scholar
  33. 33.
    Senior V, Marteau TM, Weinman J. Self-reported adherence to cholesterol-lowering medication in patients with familial hypercholesterolaemia: the role of illness perceptions. Cardiovasc Drugs Ther. 2004;18(6):475–81.Google Scholar
  34. 34.
    Sirey JA, Bruce ML, Alexopoulos GS, Perlick DA, Friedman SJ, Meyers BS. Stigma as a barrier to recovery: perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence. Psychiatr Serv. 2001;52(12):1615–20.Google Scholar
  35. 35.
    Thomas LK, Sargent RG, Michels PC, Richter DL, Valois RF, Moore CG. Identification of the factors associated with compliance to therapeutic diets in older adults with end stage renal disease. J Ren Nutr. 2001;11(2):80–9.Google Scholar
  36. 36.
    Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California medicaid program. Value Health. 2005;8(4):495–505.Google Scholar
  37. 37.
    Apter AJ, Boston RC, George M, Norfleet AL, Tenhave T, Coyne JC, et al. Modifiable barriers to adherence to inhaled steroids among adults with asthma: it's not just black and white. J Allergy Clin Immunol. 2003;111(6):1219–26.Google Scholar
  38. 38.
    Cooper C, Carpenter I, Katona C, Schroll M, Wagner C, Fialova D, et al. The AdHOC study of older adults' adherence to medication in 11 countries. Am J Geriatr Psychiatry. 2005;13(12):1067–76.Google Scholar
  39. 39.
    Turner J, Wright E, Mendella L, Anthonisen N. Predictors of patient adherence to long-term home nebulizer therapy for COPD. The IPPB study group. Intermittent positive pressure breathing. Chest. 1995;108(2):394–400.Google Scholar
  40. 40.
    Swett C Jr, Noones J. Factors associated with premature termination from outpatient treatment. Hosp Community Psychiatry. 1989;40(9):947–51.Google Scholar
  41. 41.
    Yavuz A, Tuncer M, Erdogan O, Gurkan A, Cetinkaya R, Akbas SH, et al. Is there any effect of compliance on clinical parameters of renal transplant recipients? Transplant Proc. 2004;36(1):120–1.Google Scholar
  42. 42.
    Apter AJ, Reisine ST, Affleck G, Barrows E, ZuWallack RL. Adherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief differences. Am J Respir Crit Care Med. 1998;157(6):1810–7.Google Scholar
  43. 43.
    Okuno J, Yanagi H. Tomura S. Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community? Eur J Clin Pharmacol. 2001;57(8):589–94.Google Scholar
  44. 44.
    Kyngas HA. Compliance of adolescents with asthma. Nurs Health Sci. 1999;1(3):195–202.Google Scholar
  45. 45.
    Zyczynski TM, Coyne KS. Hypertension and current issues in compliance and patient outcomes. Curr Hypertens Rep. 2000;2(6):510–4.Google Scholar
  46. 46.
    Jin J, Sklar GE, Min Sen OV, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269–86.Google Scholar
  47. 47.
    Sharkness CM, Snow DA. The patient's view of hypertension and compliance. Am J Prev Med. 1992;8(3):141–6.Google Scholar
  48. 48.
    Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160(1):31–7.Google Scholar
  49. 49.
    Garay-Sevilla ME, Nava LE, Malacara JM, Huerta R, Diaz de Leon J, Mena A, et al. Adherence to treatment and social support in patients with non-insulin dependent diabetes mellitus. J Diabetes Complicat. 1995;9(2):81–6.Google Scholar
  50. 50.
    Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26(5):1408–12.Google Scholar
  51. 51.
    Vlasnik JJ, Aliotta SL, DeLor B. Medication adherence: factors influencing compliance with prescribed medication plans. Case Manager. 2005;16(2):47–51.Google Scholar
  52. 52.
    Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. J Am Pharm Assos (Wash). 2000;40(4):475–85.Google Scholar
  53. 53.
    Murray MD, Darnell J, Weinberger M, Martz BL. Factors contributing to medication noncompliance in elderly public housing tenants. Drug Intell Clin Pharm. 1986;20(2):146–52.Google Scholar
  54. 54.
    Butterworth JR, Banfield LM, Iqbal TH, Cooper BT. Factors relating to compliance with a gluten-free diet in patients with coeliac disease: comparison of white Caucasian and south Asian patients. Clin Nutr. 2004;23(5):1127–34.Google Scholar
  55. 55.
    Ponnusankar S, Surulivelrajan M, Anandamoorthy N, Suresh B. Assessment of impact of medication counseling on patients' medication knowledge and compliance in an outpatient clinic in South India. Patient Educ Couns. 2004;54(1):55–60.Google Scholar
  56. 56.
    Moore PJ, Sickel AE, Malat J, Williams D, Jackson J, Adler NE. Psychosocial factors in medical and psychological treatment avoidance: the role of the doctor-patient relationship. J Health Psychol. 2004;9(3):421–33.Google Scholar
  57. 57.
    Stromberg A, Brostrom A, Dahlstrom U, Fridlund B. Factors influencing patient compliance with therapeutic regimens in chronic heart failure: a critical incident technique analysis. Heart Lung. 1999;28(5):334–41.Google Scholar
  58. 58.
    Lawson VL, Lyne PA, Harvey JN, Bundy CE. Understanding why people with type 1 diabetes do not attend for specialist advice: a qualitative analysis of the views of people with insulin-dependent diabetes who do not attend diabetes clinic. J Health Psychol. 2005;10(3):409–23.Google Scholar
  59. 59.
    Tamburrino MB, Nagel RW, Chahal MK, Lynch DJ. Antidepressant medication adherence: a study of primary care patients. Prim Care Companion J Clin Psychiatry. 2009;11(5):205–11.Google Scholar
  60. 60.
    Brug J, Conner M, Harre N, Kremers S, McKellar S, Whitelaw S. The transtheoretical model and stages of change: a critique: observations by five commentators on the paper by Adams, J. And white, M. (2004) why don't stage-based activity promotion interventions work? Health Educ Res. 2005;20(2):244–58.Google Scholar
  61. 61.
    Steiner JF. Rethinking adherence. Ann Intern Med. 2012;157(8):580–5.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Clinical Pharmacy and Practice Section, College of PharmacyQatar UniversityDohaQatar
  2. 2.Boden InstituteUniversity of SydneySydneyAustralia
  3. 3.Department of Community Health SciencesUCLA Fielding School of Public HealthLos AngelesUSA
  4. 4.Pharmacy DepartmentMesaimeer Healthcare CenterDohaQatar
  5. 5.Pharmacy DepartmentWestbay Healthcare CenterDohaQatar

Personalised recommendations